The DOI matches its Crossref record; 160 of the 160 references it cites were found in a registry or an index.
The Transthyretin Amyloidoses: From Delineating the Molecular Mechanism of Aggregation Linked to Pathology to a Regulatory-Agency-Approved Drug
Open accessAbstract
Transthyretin (TTR) is one of the many proteins that are known to misfold and aggregate (i.e., undergo amyloidogenesis) in vivo. The process of TTR amyloidogenesis causes nervous system and/or heart pathology. While several of these maladies are associated with mutations that destabilize the TTR native quaternary and/or tertiary structure, wild type TTR amyloidogenesis also leads to the degeneration of post-mitotic tissue. Over the past twenty years, much has been learned about the factors that influence the propensity of TTR to aggregate. This biophysical information led to the development of a therapeutic strategy, termed “kinetic stabilization”, to prevent TTR amyloidogenesis. This strategy afforded the drug, tafamidis (trade name: Vyndaqel®), which was recently approved by the European Medicines Agency for the treatment of Transthyretin Familial Amyloid Polyneuropathy (TTR-FAP), a common familial TTR amyloid disease. Tafamidis is the first, and currently the only, medication approved to treat TTR-FAP. Here we review the biophysical basis for the kinetic stabilization strategy and the structure-based drug design effort that led to this first-in-class pharmacologic agent.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Protein folding and misfolding
Dobson, C. M. (2003) · Nature · doi:10.1038/nature02261 · Cited by 4,791
Intrinsically unstructured proteins and their functions
Dyson, H. J., & Wright, P. E. (2005) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1589 · Cited by 3,871
Diffusible, nonfibrillar ligands derived from Aβ 1–42 are potent central nervous system neurotoxins
Lambert, M. P., Barlow, A. K., Chromy, B. A., Edwards, C., Freed, R., Liosatos, M., Morgan, T. E., Rozovsky, I., Trommer, B., Viola, K. L., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.11.6448 · Cited by 3,506
Adapting Proteostasis for Disease Intervention
Balch, W. E., Morimoto, R. I., Dillin, A., & Kelly, J. W. (2008) · Science · doi:10.1126/science.1141448 · Cited by 2,495
Self-citation(2016) · Lung Transplantation · doi:10.3109/9781439802571-25 · Cited by 2,157
Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective
Tanzi, R. E., & Bertram, L. (2005) · Cell · doi:10.1016/j.cell.2005.02.008 · Cited by 1,849
Prediction of sequence-dependent and mutational effects on the aggregation of peptides and proteins
Fernandez-Escamilla, A.-M., Rousseau, F., Schymkowitz, J., & Serrano, L. (2004) · Nature Biotechnology · doi:10.1038/nbt1012 · Cited by 1,658
Folding proteins in fatal ways
Selkoe, D. J. (2003) · Nature · doi:10.1038/nature02264 · Cited by 1,417
Amyloid pores from pathogenic mutations
Lashuel, H. A., Hartley, D., Petre, B. M., Walz, T., & Lansbury, P. T. (2002) · Nature · doi:10.1038/418291a · Cited by 1,289
Biological and Chemical Approaches to Diseases of Proteostasis Deficiency
Powers, E. T., Morimoto, R. I., Dillin, A., Kelly, J. W., & Balch, W. E. (2009) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.052308.114844 · Cited by 1,149
Self-citationANDRADE, C. (1952) · Brain · doi:10.1093/brain/75.3.408 · Cited by 1,074
Rationalization of the effects of mutations on peptide andprotein aggregation rates
Chiti, F., Stefani, M., Taddei, N., Ramponi, G., & Dobson, C. M. (2003) · Nature · doi:10.1038/nature01891 · Cited by 1,072
Instability, unfolding and aggregation of human lysozyme variants underlying amyloid fibrillogenesis
Booth, D. R., Sunde, M., Bellotti, V., Robinson, C. V., Hutchinson, W. L., Fraser, P. E., Hawkins, P. N., Dobson, C. M., Radford, S. E., Blake, C. C. F., et al. (1997) · Nature · doi:10.1038/385787a0 · Cited by 1,048
The alternative conformations of amyloidogenic proteins and their multi-step assembly pathways
Kelly, J. W. (1998) · Current Opinion in Structural Biology · doi:10.1016/s0959-440x(98)80016-x · Cited by 1,001
Self-citationSynaptic Targeting by Alzheimer's-Related Amyloid β Oligomers
Lacor, P. N., Buniel, M. C., Chang, L., Fernandez, S. J., Gong, Y., Viola, K. L., Lambert, M. P., Velasco, P. T., Bigio, E. H., Finch, C. E., et al. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.3432-04.2004 · Cited by 954
Opposing activities protect against age-onset proteotoxicity
Cohen, E., Bieschke, J., Perciavalle, R. M., Kelly, J. W., & Dillin, A. (2006) · Science · doi:10.1126/science.1124646 · Cited by 843
Self-citationTafamidis for transthyretin familial amyloid polyneuropathy: A randomized, controlled trial
Coelho, T., Maia, L. F., Martins da Silva, A., Waddington Cruz, M., Planté-Bordeneuve, V., Lozeron, P., Suhr, O. B., Campistol, J. M., Conceição, I. M., Schmidt, H. H.-J., et al. (2012) · Neurology · doi:10.1212/wnl.0b013e3182661eb1 · Cited by 816
Self-citationMorley, J. F., Brignull, H. R., Weyers, J. J., & Morimoto, R. I. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.152161099 · Cited by 810
Identifying the amylome, proteins capable of forming amyloid-like fibrils
Goldschmidt, L., Teng, P. K., Riek, R., & Eisenberg, D. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0915166107 · Cited by 809
Blake, C. C. F., Geisow, M. J., Oatley, S. J., Rérat, B., & Rérat, C. (1978) · Journal of Molecular Biology · doi:10.1016/0022-2836(78)90368-6 · Cited by 791
Diagnosis and Management of the Cardiac Amyloidoses
Falk, R. H. (2005) · Circulation · doi:10.1161/circulationaha.104.489187 · Cited by 791
Regulation of Longevity in Caenorhabditis elegans by Heat Shock Factor and Molecular Chaperones
Morley, J. F., & Morimoto, R. I. (2004) · Molecular Biology of the Cell · doi:10.1091/mbc.e03-07-0532 · Cited by 727
Fibril in senile systemic amyloidosis is derived from normal transthyretin.
Westermark, P., Sletten, K., Johansson, B., & Cornwell, G. G. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.7.2843 · Cited by 696
Zempel, H., Thies, E., Mandelkow, E., & Mandelkow, E.-M. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.2357-10.2010 · Cited by 686
Amyloid fibril formation by an SH3 domain
Guijarro, J. I., Sunde, M., Jones, J. A., Campbell, I. D., & Dobson, C. M. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.8.4224 · Cited by 669
Alternative conformations of amyloidogenic proteins govern their behavior
Kelly, J. W. (1996) · Current Opinion in Structural Biology · doi:10.1016/s0959-440x(96)80089-3 · Cited by 593
Self-citationHolmgren, G., Steen, L., Suhr, O., Ericzon, B.-G., Groth, C.-G., Andersen, O., Wallin, B. G., Seymour, A., Richardson, S., Hawkins, P. N., et al. (1993) · The Lancet · doi:10.1016/0140-6736(93)93127-m · Cited by 579
Lai, Z., Colón, W., & Kelly, J. W. (1996) · Biochemistry · doi:10.1021/bi952501g · Cited by 574
Self-citationPartial denaturation of transthyretin is sufficient for amyloid fibril formation in vitro
Colon, W., & Kelly, J. W. (1992) · Biochemistry · doi:10.1021/bi00151a036 · Cited by 573
Self-citationVariant-Sequence Transthyretin (Isoleucine 122) in Late-Onset Cardiac Amyloidosis in Black Americans
Jacobson, D. R., Pastore, R. D., Yaghoubian, R., Kane, I., Gallo, G., Buck, F. S., & Buxbaum, J. N. (1997) · New England Journal of Medicine · doi:10.1056/nejm199702133360703 · Cited by 554
[17] Analysis of protein aggregation kinetics
Ferrone, F. (1999) · Methods in Enzymology · doi:10.1016/s0076-6879(99)09019-9 · Cited by 539
Prevention of Transthyretin Amyloid Disease by Changing Protein Misfolding Energetics
Hammarström, P., Wiseman, R. L., Powers, E. T., & Kelly, J. W. (2003) · Science · doi:10.1126/science.1079589 · Cited by 525
Self-citationThe Biological and Chemical Basis for Tissue-Selective Amyloid Disease
Sekijima, Y., Wiseman, R. L., Matteson, J., Hammarström, P., Miller, S. R., Sawkar, A. R., Balch, W. E., & Kelly, J. W. (2005) · Cell · doi:10.1016/j.cell.2005.01.018 · Cited by 488
Self-citationReduced IGF-1 signaling delays age-associated proteotoxicity in mice
Cohen, E., Paulsson, J. F., Blinder, P., Burstyn-Cohen, T., Du, D., Estepa, G., Adame, A., Pham, H. M., Holzenberger, M., Kelly, J. W., et al. (2009) · Cell · doi:10.1016/j.cell.2009.11.014 · Cited by 488
Self-citationPrediction of Aggregation-Prone Regions in Structured Proteins
Tartaglia, G. G., Pawar, A. P., Campioni, S., Dobson, C. M., Chiti, F., & Vendruscolo, M. (2008) · Journal of Molecular Biology · doi:10.1016/j.jmb.2008.05.013 · Cited by 437
Amyloid-β immunotherapy for Alzheimer's disease: the end of the beginning
Schenk, D. (2002) · Nature Reviews Neuroscience · doi:10.1038/nrn938 · Cited by 436
Saraiva, M. J., Birken, S., Costa, P. P., & Goodman, D. S. (1984) · Journal of Clinical Investigation · doi:10.1172/jci111390 · Cited by 434
Structure of a complex of two plasma proteins: transthyretin and retinol-binding protein
Monaco, H., Rizzi, M., & Coda, A. (1995) · Science · doi:10.1126/science.7754382 · Cited by 409
Holmgren, G., Steen, L., Ekstedt, J., Groth, C., Ericzon, B. ‐., Eriksson, S., Andersen, O., Karlberg, I., Nordén, G., Nakazato, M., et al. (1991) · Clinical Genetics · doi:10.1111/j.1399-0004.1991.tb03085.x · Cited by 396
Reixach, N., Deechongkit, S., Jiang, X., Kelly, J. W., & Buxbaum, J. N. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0400062101 · Cited by 392
Self-citationAmyloid-β forms fibrils by nucleated conformational conversion of oligomers
Lee, J., Culyba, E. K., Powers, E. T., & Kelly, J. W. (2011) · Nature Chemical Biology · doi:10.1038/nchembio.624 · Cited by 381
Self-citationRational design of potent human transthyretin amyloid disease inhibitors.
Sacchettini, J. C., Klabunde, T., Petrassi, H. M., Oza, V. B., Raman, P., & Kelly, J. W. (2000) · Nature Structural Biology · doi:10.1038/74082 · Cited by 379
Self-citationNg, B., Connors, L. H., Davidoff, R., Skinner, M., & Falk, R. H. (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.12.1425 · Cited by 367
Sequence-dependent denaturation energetics: A major determinant in amyloid disease diversity
Hammarström, P., Jiang, X., Hurshman, A. R., Powers, E. T., & Kelly, J. W. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.202495199 · Cited by 359
Self-citationCan Alzheimer disease be prevented by amyloid-β immunotherapy?
Lemere, C. A., & Masliah, E. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2009.219 · Cited by 351
A role for destabilizing amino acid replacements in light-chain amyloidosis.
Hurle, M. R., Helms, L. R., Li, L., Chan, W., & Wetzel, R. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.12.5446 · Cited by 348
Deposition of Transthyretin in Early Stages of Familial Amyloidotic Polyneuropathy
Mendes Sousa, M., Cardoso, I., Fernandes, R., Guimarães, A., & Saraiva, M. J. (2001) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63050-7 · Cited by 344
Inhibiting transthyretin amyloid fibril formation via protein stabilization
Miroy, G. J., Lai, Z., Lashuel, H. A., Peterson, S. A., Strang, C., & Kelly, J. W. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.26.15051 · Cited by 344
Self-citationTransthyretin Aggregation under Partially Denaturing Conditions Is a Downhill Polymerization
Hurshman, A. R., White, J. T., Powers, E. T., & Kelly, J. W. (2004) · Biochemistry · doi:10.1021/bi049621l · Cited by 340
Self-citationHerbert, J., Wilcox, J. N., Pham, K.-T. C., Fremeau, R. T., Zeviani, M., Dwork, A., Soprano, D. R., Makover, A., Goodman, D. S., Zimmerman, E. A., et al. (1986) · Neurology · doi:10.1212/wnl.36.7.900 · Cited by 323
Prediction of the Absolute Aggregation Rates of Amyloidogenic Polypeptide Chains
DuBay, K. F., Pawar, A. P., Chiti, F., Zurdo, J., Dobson, C. M., & Vendruscolo, M. (2004) · Journal of Molecular Biology · doi:10.1016/j.jmb.2004.06.043 · Cited by 318
Partially Unfolded States of β2-Microglobulin and Amyloid Formation in Vitro
McParland, V. J., Kad, N. M., Kalverda, A. P., Brown, A., Kirwin-Jones, P., Hunter, M. G., Sunde, M., & Radford, S. E. (2000) · Biochemistry · doi:10.1021/bi000276j · Cited by 309
Johnson, S. M., Wiseman, R. L., Sekijima, Y., Green, N. S., Adamski-Werner, S. L., & Kelly, J. W. (2005) · Accounts of Chemical Research · doi:10.1021/ar020073i · Cited by 303
Self-citationBortezomib With or Without Dexamethasone in Primary Systemic (Light Chain) Amyloidosis
Kastritis, E., Wechalekar, A. D., Dimopoulos, M. A., Merlini, G., Hawkins, P. N., Perfetti, V., Gillmore, J. D., & Palladini, G. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.8220 · Cited by 298
Trans -Suppression of Misfolding in an Amyloid Disease
Hammarström, P., Schneider, F., & Kelly, J. W. (2001) · Science · doi:10.1126/science.1062245 · Cited by 293
Self-citationTransthyretin protects Alzheimer's mice from the behavioral and biochemical effects of Aβ toxicity
Buxbaum, J. N., Ye, Z., Reixach, N., Friske, L., Levy, C., Das, P., Golde, T., Masliah, E., Roberts, A. R., & Bartfai, T. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0712197105 · Cited by 284
Herlenius, G., Wilczek, H. E., Larsson, M., & Ericzon, B.-G. (2004) · Transplantation · doi:10.1097/01.tp.0000092307.98347.cb · Cited by 275
Sekijima, Y., Dendle, M. A., & Kelly, J. W. (2006) · Amyloid · doi:10.1080/13506120600960882 · Cited by 268
Self-citationTransthyretin: a review from a structural perspective
Hamilton, J. A., & Benson, M. D. (2001) · Cellular and Molecular Life Sciences · doi:10.1007/pl00000791 · Cited by 264
An Engineered Transthyretin Monomer that Is Nonamyloidogenic, Unless It Is Partially Denatured
Jiang, X., Smith, C. S., Petrassi, H. M., Hammarström, P., White, J. T., Sacchettini, J. C., & Kelly, J. W. (2001) · Biochemistry · doi:10.1021/bi011194d · Cited by 239
Self-citationA comparative analysis of 23 structures of the amyloidogenic protein transthyretin
Hörnberg, A., Eneqvist, T., Olofsson, A., Lundgren, E., & Sauer-Eriksson, A. E. (2000) · Journal of Molecular Biology · doi:10.1006/jmbi.2000.4078 · Cited by 239
Razavi, H., Palaninathan, S. K., Powers, E. T., Wiseman, R. L., Purkey, H. E., Mohamedmohaideen, N. N., Deechongkit, S., Chiang, K. P., Dendle, M. T. A., Sacchettini, J. C., et al. (2003) · Angewandte Chemie International Edition · doi:10.1002/anie.200351179 · Cited by 232
Self-citationAdamski-Werner, S. L., Palaninathan, S. K., Sacchettini, J. C., & Kelly, J. W. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm030347n · Cited by 230
Self-citationTransthyretin mutations in health and disease
João, M., & Saraiva, M. (1995) · Human Mutation · doi:10.1002/humu.1380050302 · Cited by 220
Lashuel, H. A., Lai, Z., & Kelly, J. W. (1998) · Biochemistry · doi:10.1021/bi981876+ · Cited by 206
Self-citationInhibiting transthyretin conformational changes that lead to amyloid fibril formation
Peterson, S. A., Klabunde, T., Lashuel, H. A., Purkey, H., Sacchettini, J. C., & Kelly, J. W. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.22.12956 · Cited by 206
Self-citationPowers, E. T., & Powers, D. L. (2006) · Biophysical Journal · doi:10.1529/biophysj.105.073767 · Cited by 205
Self-citationTransthyretin Quaternary and Tertiary Structural Changes Facilitate Misassembly into Amyloid
KELLY, J., COLON, W., LAI, Z., LASHUEL, H., MCCULLOCH, J., MCCUTCHEN, S., MIROY, G., & PETERSON, S. (1997) · Advances in Protein Chemistry · doi:10.1016/s0065-3233(08)60321-6 · Cited by 204
Self-citationNegative cooperativity in the binding of thyroxine to human serum prealbumin
Ferguson, R. N., Edelhoch, H., Saroff, H. A., Robbins, J., & Cahnmann, H. J. (1975) · Biochemistry · doi:10.1021/bi00673a014 · Cited by 202
Miller, S. R., Sekijima, Y., & Kelly, J. W. (2004) · Laboratory Investigation · doi:10.1038/labinvest.3700059 · Cited by 198
Self-citationComparison of Lethal and Nonlethal Transthyretin Variants and Their Relationship to Amyloid Disease
McCutchen, S. L., Lai, Z., Miroy, G. J., Kelly, J. W., & Colon, W. (1995) · Biochemistry · doi:10.1021/bi00041a032 · Cited by 198
Self-citationMcCutchen, S. L., Colon, W., & Kelly, J. W. (1993) · Biochemistry · doi:10.1021/bi00096a024 · Cited by 197
Self-citationThe Pathway by Which the Tetrameric Protein Transthyretin Dissociates
Foss, T. R., Wiseman, R. L., & Kelly, J. W. (2005) · Biochemistry · doi:10.1021/bi051608t · Cited by 193
Self-citationAmyloid imaging in aging and dementia: testing the amyloid hypothesis in vivo.
Rabinovici, G. D., & Jagust, W. J. (2009) · PubMed · doi:10.3233/ben-2009-0232 · Cited by 192
Wojtczak, A., Cody, V., Luft, J. R., & Pangborn, W. (1996) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444996003046 · Cited by 188
The Tetrameric Protein Transthyretin Dissociates to a Non-native Monomer in Solution
Quintas, A., Saraiva, M. J. M., & Brito, R. M. M. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.46.32943 · Cited by 186
Amyloid Imaging in Aging and Dementia: Testing the Amyloid Hypothesis In Vivo
Rabinovici, G. D., & Jagust, W. J. (2009) · Behavioural Neurology · doi:10.1155/2009/609839 · Cited by 185
Hou, X., Aguilar, M., & Small, D. H. (2007) · The FEBS Journal · doi:10.1111/j.1742-4658.2007.05712.x · Cited by 176
Structure-based design of kinetic stabilizers that ameliorate the transthyretin amyloidoses
Connelly, S., Choi, S., Johnson, S. M., Kelly, J. W., & Wilson, I. A. (2010) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2009.12.009 · Cited by 176
Self-citationLashuel, H. A., Wurth, C., Woo, L., & Kelly, J. W. (1999) · Biochemistry · doi:10.1021/bi991021c · Cited by 176
Self-citationNeuronal Production of Transthyretin in Human and Murine Alzheimer's Disease: Is It Protective?
Li, X., Masliah, E., Reixach, N., & Buxbaum, J. N. (2011) · Journal of Neuroscience · doi:10.1523/jneurosci.2417-11.2011 · Cited by 168
Cornwell, G. G., Sletten, K., Johansson, B., & Westermark, P. (1988) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(88)90188-x · Cited by 168
Thyroid Hormone Transport Proteins
Bartalena, L., & ROBBINS, J. J. (1993) · Clinics in Laboratory Medicine · doi:10.1016/s0272-2712(18)30427-x · Cited by 167
Jiang, X., Buxbaum, J. N., & Kelly, J. W. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.261419998 · Cited by 166
Self-citationZanotti, G., & Berni, R. (2004) · Vitamins & Hormones · doi:10.1016/s0083-6729(04)69010-8 · Cited by 162
Progression of transthyretin amyloid neuropathy after liver transplantation
Liepnieks, J. J., Zhang, L. Q., & Benson, M. D. (2010) · Neurology · doi:10.1212/wnl.0b013e3181ea15d4 · Cited by 158
Purkey, H. E., Palaninathan, S. K., Kent, K. C., Smith, C., Safe, S. H., Sacchettini, J. C., & Kelly, J. W. (2004) · Chemistry & Biology · doi:10.1016/j.chembiol.2004.10.009 · Cited by 158
Self-citationOlofsson, B., Backman, C., Karp, K. H., & Suhr, O. B. (2002) · Transplantation · doi:10.1097/00007890-200203150-00015 · Cited by 157
Tojo, K., Sekijima, Y., Kelly, J. W., & Ikeda, S. (2006) · Neuroscience Research · doi:10.1016/j.neures.2006.08.014 · Cited by 153
Self-citationTargeted suppression of an amyloidogenic transthyretin with antisense oligonucleotides
Benson, M. D., Kluve‐Beckerman, B., Zeldenrust, S. R., Siesky, A. M., Bodenmiller, D. M., Showalter, A. D., & Sloop, K. W. (2006) · Muscle & Nerve · doi:10.1002/mus.20503 · Cited by 150
Human β-Secretase (BACE) and BACE Inhibitors
John, V., Beck, J. P., Bienkowski, M. J., Sinha, S., & Heinrikson, R. L. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm030247h · Cited by 147
Discovering transthyretin amyloid fibril inhibitors by limited screening
Baures, P. W., Peterson, S., & Kelly, J. W. (1998) · Bioorganic & Medicinal Chemistry · doi:10.1016/s0968-0896(98)00130-8 · Cited by 141
Self-citationPathogenesis of and Therapeutic Strategies to Ameliorate the Transthyretin Amyloidoses
Sekijima, Y., Kelly, J. W., & Ikeda, S. (2008) · Current Pharmaceutical Design · doi:10.2174/138161208786404155 · Cited by 139
Self-citationA glimpse of a possible amyloidogenic intermediate of transthyretin.
Wemmer, D. E., Liu, K., Cho, H. S., et al. (2000) · Nature Structural Biology · doi:10.1038/78980 · Cited by 138
Hurshman, A. R., Powers, E. T., & Kelly, J. W. (2008) · Biochemistry · doi:10.1021/bi800636q · Cited by 138
Self-citationJohnson, S. M., Connelly, S., Wilson, I. A., & Kelly, J. W. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm0708735 · Cited by 136
Self-citationBaures, P. W., Oza, V. B., Peterson, S., & Kelly, J. W. (1999) · Bioorganic & Medicinal Chemistry · doi:10.1016/s0968-0896(99)00066-8 · Cited by 135
Self-citationSequence Communication: Tabulation of transthyretin (TTR) variants as of 1/1/2000
Connors, L. H., Richardson, A. M., Théberge, R., & Costello, C. E. (2000) · Amyloid · doi:10.3109/13506120009146826 · Cited by 132
Neurodegeneration in familial amyloid polyneuropathy: from pathology to molecular signaling
Sousa, M. M., & Saraiva, M. J. (2003) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2003.11.002 · Cited by 132
Transport of Thyroid Hormones in Serum and Cerebrospinal Fluid1
Hagen, G. A., & Elliott, W. J. (1973) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-37-3-415 · Cited by 132
A PECULIAR FORM OF PERIPHERAL NEUROPATHY
Andrade, C. (1951) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1951.tb09673.x · Cited by 130
Familial amyloidotic polyneuropathy
Benson, M. D., & Roudebush, R. L. (1989) · Trends in Neurosciences · doi:10.1016/0166-2236(89)90162-8 · Cited by 125
Evaluating the binding selectivity of transthyretin amyloid fibril inhibitors in blood plasma
Purkey, H. E., Dorrell, M. I., & Kelly, J. W. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.091431798 · Cited by 124
Self-citationMechanisms of transthyretin cardiomyocyte toxicity inhibition by resveratrol analogs
Bourgault, S., Choi, S., Buxbaum, J. N., Kelly, J. W., Price, J. L., & Reixach, N. (2011) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2011.04.133 · Cited by 115
Self-citationLigand binding to distinct states diverts aggregation of an amyloid-forming protein
Woods, L. A., Platt, G. W., Hellewell, A. L., Hewitt, E. W., Homans, S. W., Ashcroft, A. E., & Radford, S. E. (2011) · Nature Chemical Biology · doi:10.1038/nchembio.635 · Cited by 113
Evidence for Early Cytotoxic Aggregates in Transgenic Mice for Human Transthyretin Leu55Pro
Sousa, M. M., Fernandes, R., Palha, J. A., Taboada, A., Vieira, P., & Saraiva, M. J. (2002) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)64469-0 · Cited by 110
Autonomic dysfunction in familial amyloidotic polyneuropathy (FAP)
Ando, Y., & Suhr, O. B. (1998) · Amyloid · doi:10.3109/13506129809007303 · Cited by 108
Schneider, F., Hammarström, P., & Kelly, J. W. (2001) · Protein Science · doi:10.1110/ps.8901 · Cited by 105
Self-citationKinetic Stabilization of an Oligomeric Protein by a Single Ligand Binding Event
Wiseman, R. L., Johnson, S. M., Kelker, M. S., Foss, T. R., Wilson, I. A., & Kelly, J. W. (2005) · Journal of the American Chemical Society · doi:10.1021/ja042929f · Cited by 104
Self-citationModeling Polyglutamine Pathogenesis in C. elegans
Brignull, H. R., Morley, J. F., Garcia, S. M. D. A., & Morimoto, R. I. (2006) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(06)12016-9 · Cited by 103
Bourgault, S., Solomon, J. P., Reixach, N., & Kelly, J. W. (2010) · Biochemistry · doi:10.1021/bi101822y · Cited by 103
Self-citationBisaryloxime Ethers as Potent Inhibitors of Transthyretin Amyloid Fibril Formation
Johnson, S. M., Petrassi, H. M., Palaninathan, S. K., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm049274d · Cited by 102
Self-citationScreening Transthyretin Amyloid Fibril Inhibitors
McCammon, M. G., Scott, D. J., Keetch, C. A., Greene, L. H., Purkey, H. E., Petrassi, H. M., Kelly, J. W., & Robinson, C. V. (2002) · Structure · doi:10.1016/s0969-2126(02)00771-2 · Cited by 101
Self-citationGertz, M. A. (2010) · American Journal of Hematology · doi:10.1002/ajh.21934 · Cited by 100
Familial amyloid polyneuropathy: new developments in genetics and treatment
Coelho, T. (1996) · Current Opinion in Neurology · doi:10.1097/00019052-199610000-00007 · Cited by 100
Bortezomib in the treatment of AL amyloidosis: targeted therapy?
Sitia, R., Palladini, G. O., & Merlini, G. (2007) · Haematologica · doi:10.3324/haematol.12136 · Cited by 95
Variations in Thyroid Hormone Transport Proteins and Their Clinical Implications
Bartalena, L., & ROBBINS, J. J. (1992) · Thyroid · doi:10.1089/thy.1992.2.237 · Cited by 92
Johnson, S. M., Connelly, S., Wilson, I. A., & Kelly, J. W. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm801347s · Cited by 91
Self-citationStress, Aging, and Neurodegenerative Disease
Morimoto, R. I. (2006) · New England Journal of Medicine · doi:10.1056/nejmcibr065573 · Cited by 91
Chemoselective small molecules that covalently modify one lysine in a non-enzyme protein in plasma
Choi, S., Connelly, S., Reixach, N., Wilson, I. A., & Kelly, J. W. (2010) · Nature Chemical Biology · doi:10.1038/nchembio.281 · Cited by 90
Self-citationGreen, N. S., Palaninathan, S. K., Sacchettini, J. C., & Kelly, J. W. (2003) · Journal of the American Chemical Society · doi:10.1021/ja030294z · Cited by 88
Self-citationPotent Kinetic Stabilizers That Prevent Transthyretin-Mediated Cardiomyocyte Proteotoxicity
Alhamadsheh, M. M., Connelly, S., Cho, A., Reixach, N., Powers, E. T., Pan, D. W., Wilson, I. A., Kelly, J. W., & Graef, I. A. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002473 · Cited by 86
Self-citationWhite, J. T., & Kelly, J. W. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.241406698 · Cited by 86
Self-citationStructure-Based Design of N-Phenyl Phenoxazine Transthyretin Amyloid Fibril Inhibitors
Petrassi, H. M., Klabunde, T., Sacchettini, J. C., & Kelly, J. W. (2000) · Journal of the American Chemical Society · doi:10.1021/ja993309v · Cited by 84
Self-citationPalaninathan, S. K., Mohamedmohaideen, N. N., Snee, W. C., Kelly, J. W., & Sacchettini, J. C. (2008) · Journal of Molecular Biology · doi:10.1016/j.jmb.2008.07.029 · Cited by 84
Self-citationWojtczak, A., Luft, J. R., & Cody, V. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)48501-8 · Cited by 84
Kopelman, M., Cogan, U., Mokady, S., & Shinitzky, M. (1976) · Biochimica et Biophysica Acta (BBA) - Protein Structure · doi:10.1016/0005-2795(76)90082-9 · Cited by 83
Johnson, S. M., Connelly, S., Wilson, I. A., & Kelly, J. W. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm800435s · Cited by 81
Self-citationSuhr, O. B., Hietala, S.-O., Riklund, K., Pepys, M. B., Hawkins, P. N., & Rydh, A. (1998) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s002590050273 · Cited by 80
Familial amyloid polyneuropathy: new developments in genetics and treatment.
Coelho, T. (1996) · PubMed · Cited by 79
Foss, T. R., Kelker, M. S., Wiseman, R. L., Wilson, I. A., & Kelly, J. W. (2005) · Journal of Molecular Biology · doi:10.1016/j.jmb.2005.01.050 · Cited by 79
Self-citationSynthesis and evaluation of anthranilic acid-based transthyretin amyloid fibril inhibitors
Oza, V. B., Petrassi, H. M., Purkey, H. E., & Kelly, J. W. (1999) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(98)00696-9 · Cited by 78
Self-citationHammarström, P., Jiang, X., Deechongkit, S., et al. (2001) · Biochemistry · doi:10.1021/bi010673+ · Cited by 75
Chan, P., Pardon, E., Menzer, L., Genst, E. D., Kumita, J. R., Christodoulou, J., Saerens, D., Brans, A., Bouillenne, F., Archer, D. B., et al. (2008) · Biochemistry · doi:10.1021/bi8005797 · Cited by 72
Aging as a major risk for degenerative diseases of the central nervous system
Amaducci, L. A., & Tesco, G. (1994) · Current Opinion in Neurology · doi:10.1097/00019052-199408000-00001 · Cited by 71
Choi, S., Reixach, N., Connelly, S., Johnson, S. M., Wilson, I. A., & Kelly, J. W. (2009) · Journal of the American Chemical Society · doi:10.1021/ja908562q · Cited by 70
Self-citationTargets for AD treatment: conflicting messages from γ-secretase inhibitors
Sambamurti, K., Greig, N. H., Utsuki, T., Barnwell, E., Sharma, E., Mazell, C., Bhat, N. R., Kindy, M. S., Lahiri, D. K., & Pappolla, M. A. (2011) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07213.x · Cited by 68
Small Transthyretin (TTR) Ligands as Possible Therapeutic Agents in TTR Amyloidoses
Almeida, M. R., Gales, L., Damas, A. M., Cardoso, I., & Saraiva, M. J. (2005) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/156800705774322076 · Cited by 68
Trapping of palindromic ligands within native transthyretin prevents amyloid formation
Kolstoe, S. E., Mangione, P. P., Bellotti, V., Taylor, G. W., Tennent, G. A., Deroo, S., Morrison, A. J., Cobb, A. J. A., Coyne, A. G., McCammon, M. G., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1008255107 · Cited by 68
Binding and stabilization of transthyretin by curcumin
Pullakhandam, R., Srinivas, P. N. B. S., Nair, M. K., & Reddy, G. B. (2009) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2009.02.013 · Cited by 66
Wiseman, R. L., Green, N. S., & Kelly, J. W. (2005) · Biochemistry · doi:10.1021/bi050352o · Cited by 65
Self-citationWiseman, R. L., Powers, E. T., & Kelly, J. W. (2005) · Biochemistry · doi:10.1021/bi0511484 · Cited by 65
Self-citationCoelho, T., Chorão, R., Sousa, A., Alves, I. L., Torres, M. F., & Saraiva, M. J. (1996) · Neuromuscular Disorders · doi:10.1016/0960-8966(96)88826-2 · Cited by 61
Does citrate transport supply both acetyl groups and NADPH for cytoplasmic fatty acid synthesis?
Conover, T. E. (1987) · Trends in Biochemical Sciences · doi:10.1016/0968-0004(87)90042-9 · Cited by 53
Schormann, N., Murrell, J. R., & Benson, M. D. (1998) · Amyloid · doi:10.3109/13506129809003843 · Cited by 51
Choi, S., Ong, D. S. T., & Kelly, J. W. (2010) · Journal of the American Chemical Society · doi:10.1021/ja104999v · Cited by 51
Self-citationChoi, S., & Kelly, J. W. (2010) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2010.12.050 · Cited by 49
Self-citationStructure, mechanism and inhibition of γ-secretase and presenilin-like proteases
Wolfe, M. S. (2010) · Biological Chemistry · doi:10.1515/bc.2010.086 · Cited by 48
Hypokalemic periodic paralysis mutations: Confirmation of mutation and analysis of founder effect
Grosson, C. L. S., Esteban‐Pérez, J., McKenna-Yasek, D. M., Gusella, J. F., & Brown, R. H. (1996) · Neuromuscular Disorders · doi:10.1016/0960-8966(95)00018-6 · Cited by 47
Cell based screening of inhibitors of transthyretin aggregation
Reixach, N., Adamski‐Werner, S. L., Kelly, J. W., et al. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.07.109 · Cited by 45
Self-citationSuppression of choroid plexus transthyretin levels by antisense oligonucleotide treatment
Benson, M. D., Smith, R. A., Hung, G., Kluve‐Beckerman, B., Showalter, A. D., Sloop, K. W., & Monia, B. P. (2010) · Amyloid · doi:10.3109/13506129.2010.483121 · Cited by 44
Trivella, D. B. B., Bleicher, L., Palmieri, L. D. C., Wiggers, H. J., Montanari, C. A., Kelly, J. W., Lima, L. M. T. R., Foguel, D., & Polikarpov, I. (2010) · Journal of Structural Biology · doi:10.1016/j.jsb.2010.03.002 · Cited by 41
Self-citationColón, W., Lai, Z., McCutchen, S. L., Miroy, G. J., Strang, C. J., & Kelly, J. W. (2007) · Novartis Foundation symposium · doi:10.1002/9780470514924.ch14 · Cited by 40
Self-citationHopes remain for an Alzheimer's vaccine
Schenk, D. (2004) · Nature · doi:10.1038/431398b · Cited by 30
Familial and Senile Amyloidosis Caused by Transthyretin
Zeldenrust, S. R., & Benson, M. D. (2010) · doi:10.1002/9780470572702.ch36 · Cited by 25
Gupta, S., Chhibber, M., Sinha, S., et al. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm0700159 · Cited by 22
Bellotti, V., & Stoppini, M. (2009) · The Open Biology Journal · doi:10.2174/1874196700902010228 · Cited by 21
Transthyretin and the Transthyretin Amyloidoses
Buxbaum, J. N. (2007) · Springer eBooks · doi:10.1007/978-0-387-36534-3_13 · Cited by 16
α-Synuclein gene duplications in sporadic Parkinson disease
Theuns, J., & Broeckhoven, C. V. (2007) · Neurology · doi:10.1212/01.wnl.0000295508.10258.6b · Cited by 13
Cited by
The Amyloid State of Proteins in Human Diseases
Eisenberg, D., & Jucker, M. (2012) · Cell · doi:10.1016/j.cell.2012.02.022 · Cited by 1,744
Self-propagation of pathogenic protein aggregates in neurodegenerative diseases
Jucker, M., & Walker, L. C. (2013) · Nature · doi:10.1038/nature12481 · Cited by 1,663
Wechalekar, A. D., Gillmore, J. D., & Hawkins, P. N. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01274-x · Cited by 994
Bozkurt, B., Colvin, M., Cook, J., Cooper, L. T., Deswal, A., Fonarow, G. C., Francis, G. S., Lenihan, D., Lewis, E. F., McNamara, D. M., et al. (2016) · Circulation · doi:10.1161/cir.0000000000000455 · Cited by 891
Spreading of pathology in neurodegenerative diseases: a focus on human studies
Brettschneider, J., Tredici, K. D., Lee, V. M.-Y., & Trojanowski, J. Q. (2015) · Nature Reviews Neuroscience · doi:10.1038/nrn3887 · Cited by 790
Metadata
- Authors
- Johnson, S. M., Connelly, S., Fearns, C., Powers, E. T., & Kelly, J. W.
- Venue
- Journal of Molecular Biology
- Publisher
- Elsevier BV
- Published
- 2012-08
- Volume
- 421
- Issue
- 2-3
- Pages
- 185-203
- ISSN
- 0022-2836 (ISSN-L)
- OpenAlex
- W2015219413
- Cited by
- 328
- References
- 160
- FWCI
- 13.36
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.